Assertio Therapeutics

Assertio Therapeutics, Inc. (formerly Depomed, Inc.) is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and drug Administration (FDA). On August 15,2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.

   This article is a medical stub. You can help WikiMD by expanding it!

• Logo of Assertio Therapeutics
  Logo of Assertio Therapeutics